Ker­ris­dale 2-0 this week: Bavar­i­an Nordic's can­cer vac­cine is a bust in PhI­II

An­oth­er can­cer vac­cine has bit­ten the dust.

Six long years af­ter start­ing their Phase III tri­al for the prostate can­cer vac­cine Prost­vac, an in­de­pen­dent mon­i­tor­ing com­mit­tee says it’s time to sim­ply scrap Bavar­i­an Nordic’s {$BA­VA.CO} study af­ter con­clud­ing it wasn’t work­ing at a fi­nal in­ter­im analy­sis stage.

In­vestors who had stuck with the Dan­ish biotech weren’t pleased. Its shares lost half their val­ue, and one an­a­lyst, Pe­ter Welford at Jef­feries, says the flop could read through to a fol­low up pro­gram. He wrote:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER